Announcement on Change of Sponsor Representative for Continuous Supervision
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Change of Sponsor Representative for Continuous Supervision
Filed with SSE ·
On 6ix: 6ix.com/news/announcement-on-change-of-sponsor-representative-for-continuous-supervision-252
6ix hasn’t read this filing yet.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. on 6ix
Earlier from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Announcement on Earnings Preannouncement for 2025
- Announcement on the Acceptance of the Drug Marketing Application for Aminolevulinic Acid Hydrochloride Powder for Oral Solution for Visualization in Glioma Surgery
- Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Application Acceptance Notice for FZ-P001 Sodium Injection for Intraoperative Visualization of Malignant Lesions in Known or Suspected Lung Cancer Patients
Later from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary Procedure
- Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
- Report for Q1 2026
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical